Bristol-Myers Squibb Company stock (US0897961004): ASCO 2026 mezigdomide data in focus after Phase 3 SUCCESSOR-2 update

Bristol-Myers Squibb Company stock on the New York Stock Exchange is drawing attention as the United States-based biopharma group updates investors on late-breaking Phase 3 SUCCESSOR-2 data for its CELMoD candidate mezigdomide in relapsed or refractory multiple myeloma, showcased at the American Society of Clinical Oncology (ASCO) 2026 meeting and released via a Business Wire statement on 05/28/2026.Bristol Myers Squibb press release as of 05/28/2026

In the release, the company headquartered in Princeton, New Jersey, reported that mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) delivered a clinically meaningful and statistically significant improvement in progression-free survival in the Phase 3 trial versus carfilzomib and dexamethasone alone (Kd), with median progression-free survival of 18 months compared with 8.3 months and a hazard ratio of 0.48, corresponding to a 52% reduction in the risk of disease progression or death in relapsed or refractory multiple myeloma patients.Bristol Myers Squibb press release as of 05/28/2026

The stock traded at around USD 41 on 05/29/2026 on the NYSE under the ticker BMY as investors assessed the ASCO 2026 oncology data in the context of the companys broader hematology portfolio and its efforts to extend the Revlimid franchise lifecycle, according to price information from the New York Stock Exchange as of 05/29/2026.NYSE as of 05/29/2026

For German investors, Bristol-Myers Squibb Company is also available via Tradegate, where the stock changed hands at roughly 38 EUR on 05/29/2026, based on Tradegate price data as of that date.Tradegate as of 05/29/2026

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

Bristol-Myers Squibb Company: core business model

The group focuses on discovering, developing and commercializing prescription medicines in oncology, hematology, cardiovascular and immunology, with revenue heavily influenced by uptake of key brands such as Opdivo, Eliquis and newer pipeline assets like mezigdomide and other CELMoD agents in major markets including the United States and Europe.

Recent corporate actions

Beyond the SUCCESSOR-2 data, Bristol-Myers Squibb has been active in external innovation, including a collaboration with Chinas Jiangsu Hengrui Pharmaceuticals announced in 2025 that could reach up to USD 15.2 billion in value to co-develop a portfolio of oncology and cardiovascular drug candidates, underscoring the companys strategy to bolster its pipeline through business development alongside internal research.BioWorld as of 03/2025

Insider activity and ownership structure

As of the latest available filings with the U.S. Securities and Exchange Commission in 2026, Bristol-Myers Squibb reports a shareholder base dominated by large institutional investors, including major U.S. asset managers and index funds, reflecting its role as a significant component of key U.S. equity benchmarks such as the S&P 500, with insiders holding only a small fraction of the outstanding common stock based on recent proxy and ownership disclosures.SEC proxy filing as of 2026

Recent Form 4 filings with the SEC in early 2026 show routine equity compensation transactions by senior executives and directors, such as option exercises and restricted stock unit vesting, rather than large open-market share purchases or disposals, suggesting that insider dealing activity has mainly reflected compensation programs rather than signaling-driven trades over the past few months.SEC Form 4 feed as of 2026

Conclusion

The latest Phase 3 SUCCESSOR-2 data for mezigdomide, presented at ASCO 2026 and released on 05/28/2026, underline Bristol-Myers Squibbs ambition to reinforce its hematology franchise with next-generation CELMoD therapies that offer improved progression-free survival over current standards in relapsed or refractory multiple myeloma.

With the stock trading around USD 41 on the NYSE on 05/29/2026, investors continue to weigh the potential for mezigdomide and related assets to offset declining contributions from older products while considering the companys broader business development activities and institutional ownership profile.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.